Comprehensive review of postmenopausal osteoporosis: molecular mechanisms, lifestyle interventions and pharmacological advances
DOI:
https://doi.org/10.18203/2320-6012.ijrms20261368Keywords:
Postmenopausal osteoporosis, Hormone replacement therapy, Bone mineral density, Osteoporosis treatmentAbstract
Postmenopausal osteoporosis is a major public health concern characterized by decreased bone mineral density (BMD) and deterioration of bone microarchitecture, leading to increased fragility and fracture risk. The condition is primarily driven by estrogen deficiency following menopause, which disrupts the balance between bone resorption and bone formation. This review provides a comprehensive overview of the molecular and physiological mechanisms underlying postmenopausal osteoporosis, including the roles of osteoclast activation, inflammatory cytokines, oxidative stress, and key regulatory pathways such as RANK/RANKL/OPG and Wnt/β-catenin signaling. In addition to the biological mechanisms, the review examines important lifestyle factors that influence bone health, including nutrition, adequate calcium and vitamin D intake, physical activity, and fall-prevention strategies. Evidence supporting weight-bearing and resistance exercise as effective non-pharmacological interventions for maintaining or improving BMD is discussed. The article also reviews current pharmacological treatments for postmenopausal osteoporosis, including antiresorptive agents such as bisphosphonates and denosumab, as well as anabolic therapies such as teriparatide and romosozumab. In addition, the role of hormone replacement therapy (HRT) is considered as a therapeutic option for postmenopausal women. HRT can reduce bone loss by compensating for estrogen deficiency and has been shown to improve BMD and reduce fracture risk. Emerging therapeutic approaches and future directions in osteoporosis research are also highlighted. Understanding the complex interactions among hormonal changes, molecular pathways, lifestyle factors, and pharmacological therapies is essential for improving prevention strategies and optimizing clinical management of postmenopausal osteoporosis.
References
Almeida M, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK, Kousteni S, et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Bio Chem. 2007;282:27285-97.
Quattrini S, Pampaloni B, Gronchi G, Giusti F, Brandi ML. The Mediterranean diet in osteoporosis prevention: An insight in a peri- and post-menopausal population. Nutrients. 2021;13(2):531.
Ammann P, Rizzoli R, Bonjour J, Bourrin S, Meyer J, Vassalli P, et al. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Investigat. 1997;99:1699-703.
Anastasilakis AD, Polyzos SA, Makras P. Rebound-associated vertebral fractures after denosumab discontinuation. Eur J Endocrinol. 2017;176(6):L1-3.
Andersen TL, Søndergaard TE, Skorzynska KE, Dagnaes-Hansen F, Plesner TL, Hauge EM . et al. A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol. 2009;174:239-47.
Babhulkar S, Babhulkar S. Prevalence and related risk factors of osteoporosis in peri- and postmenopausal Indian women. J Mid-Life Health. 2013;4(3):167-72.
Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone. 2011;48:677-92.
Bartl R, Frisch B. Osteoporosis: Diagnosis, prevention, therapy. Springer. 2009;119-124.
Bhatnagar A, Kekatpure A. Postmenopausal osteoporosis: A literature review. Cureus. 2022;14(10):e30438.
Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. The Lancet. 1996;348(9041):1535-41.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Eng J Med. 2007;356(18):1809-22.
Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, et al. Odanacatib for the treatment of postmenopausal osteoporosis: Results of a long-term extension study. J Bone Mineral Res. 2021;36:1772-85.
Bone HG, et al. Effects of romosozumab treatment on bone mineral density and fracture risk in postmenopausal women with osteoporosis. J Bone Mineral Res. 2022;37(1):156-66.
Bone HG, Wagman RB, Brandi ML, Wagman RB, Maria LB, Jacques PB, Roland C, Steven RC, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the FREEDOM extension trial. Lancet Diabetes Endocrinol. 2017;5(7):513-23.
Bonewald LF. The amazing osteocyte. J Bone Mineral Res. 2011;26:229-38.
Castiglioni S, Cazzaniga A, Albisetti W, Maier JAM. Magnesium and osteoporosis: Current state of knowledge and future research directions. Nutrients. 2013;5:3022-33.
Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-α. J Clin Investig. 2000;106:1229-37.
Chang J, Wang Z, Tang E, Fan Z, McCauley L, Franceschi R, et al. Inhibition of osteoblastic bone formation by nuclear factor-KappaB. Nature Med. 2009;15:682-9.
Chen LR, et al. Dietary factors and osteoporosis risk. Nutrients. 2020;12:2347.
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Eng J Med. 2016;375(16):1532-43.
Cummings SR, Javier SM, Michael RMc, Ethel SS, Richard E, Ian RR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Eng J Med. 2009;361(8):756-65.
Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from the MORE randomized trial. J Bone Mineral Res. 2004;19(1):105-14.
Drake MT, Clarke BL, Khosla S. Bisphosphonates: Mechanism of action and role in clinical practice. Endocrine Rev. 2008;29:308-32.
Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol. 2019;104(5):1595-622.
Favus MJ. Bisphosphonates for osteoporosis. N Eng J Med. 2010;363:2027-35.
Gennari L, Fischer K, Agnusdei D. Nutrition-based support for osteoporosis in postmenopausal women: A review of recent evidence. Nutrients. 2021;13(11):3909.
Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Mineral Res. 2001;16:1575-82.
Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999;140:4367-70.
Holick MF, Neil CB, Heike AB-F, Catherine MG, David AH, Robert PH, et al. Evaluation, treatment, and prevention of vitamin D deficiency. J Clin Endocrinol Metab. 2011;96(7):1911-30.
Iwamoto R, Koide M, Udagawa N, Kobayashi Y. Positive and negative regulators of sclerostin expression. Int J Molecular Sci. 2022;23:4895.
Ji MX, Yu Q, Cheng XG. Primary osteoporosis in postmenopausal women. Chronic Dis Translat Med. 2015;1:9-13.
Kearns AE, Khosla S, Kostenuik PJ. RANKL and osteoprotegerin regulation of bone remodeling. Endocrine Rev. 2008;29:155-92.
Kirkland JL, et al. Cellular senescence and osteoporosis. Nature Rev Endocrinol. 2018;14:523-34.
Kohrt WM, Bloomfield SA, Little KD, Nelson ME, Yingling VR. Physical activity and bone health. Med Sci Sports Exercise. 2004;36:1985-96.
Lerner UH. Bone remodeling in post-menopausal osteoporosis. J Dental Res. 2006;85:584-95.
Lewiecki EM. Prevention and treatment of postmenopausal osteoporosis. Obstet Gynecol Clin N Am. 2008;35:301-15.
Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. N Eng J Med. 1995;332:305-11.
Manolagas SC, Almeida M. Oxidative stress in age-related bone loss. Molecular Endocrinol. 2007;21:2605-14.
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Eng J Med. 2001;344(19):1434-41.
Nakamura T, Imai Y, Matsumoto T, Shingo S, Kazusane T, Katsuhide I, et al. Estrogen prevents bone loss via ER-α and induction of Fas ligand in osteoclasts. Cell. 2007;130(5):811-23.
Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts. Proceed National Academy of Sci. 2009;105:20764-9.
Reid IR, Horne AM, Mihov B, Gamble GD, Al-Abuwsi F, Barker D, et al. Effects of vitamin D supplements on bone mineral density: A systematic review and meta-analysis. J Bone Mineral Res. 2018;33(7):1271-8.
Rittweger J. Mechanical loading and bone adaptation. J Musculosk Neuronal Interact. 2010;10:56-60.
Saag KG, Petersen J, Brandi ML, Andrew CK, Mattias L, Thierry T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Eng J Med. 2017;377(15):1417-27.
Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk after denosumab discontinuation. Bone, 2017;105:11-7.
Zhang Y, Liang J, Liu P, Wang Q, Liu L, Zhao H. The RANK/RANKL/OPG system and tumor bone metastasis. Front Endocrinol. 2022;13:1063815.
Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metabolism. 2006;4:111-21.
Downloads
Published
How to Cite
Issue
Section
